LNCaP-luc-M6 Bioware® Cell Line
Overview
The LNCaP-luc-M6 Bioware® Cell Line (P/N 119271) is a light producing cell line derived from LNCaP human adenocarcinoma cells by stable transfection of the North American Firefly Luciferase gene expressed from the CMV promoter. Selection Marker: Neomycin (G418 Sensitivity: 0.3 mg/ml).
Tissue: Human: prostate; metastatic site: left supraclavicular lymph node; carcinoma
Parental Line Source: American Type Culture Collection
Bioluminescence In Vitro: Approx. 2-4 photons/sec/cell, subject to imaging and culturing conditions
In Vivo Models Tested:
Nu/nu (Harlan and CR): subcutaneous (low tumor take)
SCID-bg (CR): subcutaneous with mainly lung metastasis, orthotopic with mainly lung metastasis
NOTE: Nu/nu mice are not recommended for LNCap-luc-M6 tumor growth. In SCID-bg mice tumor take is also somewhat variable.
Applications
The LNCaP-luc-M6 Bioware® Cell Line (P/N 119271) can be used in vivo to establish subcutaneous tumor model, subcutaneous tumor model with lung metastases and orthotopic prostate tumor model with lung metastases (all in SCID-bg mice). Pulmonary micrometastatic lesions were detected as early as seven weeks in the subcutaneous model and ten weeks in the orthotopic model. Ex vivo imaging confirmed the presence of bioluminescent micrometastases in the lungs of these animals. Bioluminescent imaging detected tumor cells throughout the experiment; tumors may be measured by caliper around seven weeks after the subcutaneous implantation.
